The RB1 gene was down-regulated in TKI-resistant PC-9/AB2 cells with combination treatment, therefore we hypothesized that inhibition of the pRb pathway by PD 0332991 contributes to the anti-cancer effects of gefitinib in TKI-resistant NSCLC cells. This evidence concerns the gene RB1 and cancer.